Tukysa (Tucatinib)

Tukysa is a kinase inhibitor, used along with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2 +Ve breast cancer, including patients with brain metastases, who have received single or multiple prior anti-HER2-based regimens in the metastatic setting.

 Recommended Dosage: The recommended dosage is 300 mg taken orally twice daily along with trastuzumab and capecitabine until disease progression or unacceptable toxicity. Patients should swallow tucatinib tablets whole without chewing, crushing, or splitting. Patients should not ingest the tablets in case it is broken, cracked, or not otherwise intact. Tablets should be taken approximately 12 hours apart and persistently each day with or without a meal. 

When given along with Tucatinib, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes after taking a meal. Tucatinib and capecitabine typically can be taken around the same time.

• The tucatinib 50 mg tablets can cause severe diarrhea including hypotension, acute kidney injury, dehydration and death. If diarrhea occurs, administer antidiarrheal therapy. 
• Diagnostic tests need to be performed to exclude the other causes of diarrhea. On behalf of the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue therapy. 
• The tucatinib tablets 50 mg can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting treatment, every 3 weeks during treatment. On behalf of the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue therapy. 
• Females of reproductive potential should use apt contraception during treatment and for at least 7 days after the final dose.
• Findings and its mechanism of action suggest that treatment with tukysa 150 mg tablets can cause fetal harm if administered to a pregnant woman.
• Male patients with female partners of reproductive age or potential should use effective contraception during treatment with Tucatinib and for at least 7 days after the final dose. 
• Due to the potential for severe adverse reactions in a breastfed child, women should not breastfeed during treatment with Tucatinib and for at least 7 days after the final dose.

What documents are required to import Tukysa? 

Tukysa (Tucatinib) tablets can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s ID proof (issued by the Government of the respective country).

How is the order confirmed? 

The order will be confirmed only after the receipt of:

• A valid prescription from a doctor.
• Import permit if applicable.

Is Tukysa available worldwide?

Tukysa (Tucatinib) tablet is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.

Indian Pharma Network (IPN) facilitates the import of critical medications like Tukysa (Tucatinib) globally, ensuring the named patient supply (NPS). IPN is the facilitator that provides essential support for:

• Availability of Tukysa (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka).
• Tukysa available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow,  Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc
• Determining Medicine Price.
• Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
• Ensuring 100% transparency.

Tukysa (Tucatinib) can be made available to patients, doctors, and hospitals in various countries across the globe. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit.

Indian Pharma Network (IPN) can facilitate the supply of Tukysa (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable).

For inquiries about the price of Tukysa, please contact:

We assure quality and worldwide delivery as per the buyer’s specifications.

What is the Generic Name for the trade name drug Tukysa®?

Tucatinib is Generic Name for the trade name drug Tukysa®.

What is the Manufacturer Name of Tukysa®?

Tukysa® is manufactured by Seattle Genetics, Inc.

Is Tukysa® approved by the FDA?

Yes, Tukysa® is approved by the FDA. Date of approval: On April 17, 2020.

What is Tukysa®?

Tukysa (tucatinib tablets 50mg/150mg) specifically is a tyrosine kinase inhibitor (targeted therapy) that typically targets HER2 found on some types of breast cancer cells.

What is the dosage and form of Tukysa® supplied?

Tukysa® is supplied as Tablets: 50 mg and 150 mg for oral administration.

What are the most common side effects due to Tukysa®?

Most common side effects due to Tukysa® include: rash, diarrhea, palmar-plantar erythrodysesthesia, abdominal pain, hepatotoxicity, vomiting, nausea, fatigue, stomatitis, decreased appetite, headache and anemia.

How much does Tukysa cost in India?

The tukysa cost in India is sensibly reasonable. To procure this HER2-positive breast cancer medicine authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Tukysa®?

Store tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). Dispense in original container only. Store in the original container for protection from moisture. Replace cap securely every time after opening. Do not discard desiccant.

What recent clinical trials support Tukysa’s use? 

Recent trials like the HER2CLIMB study have shown that Tukysa, when combined with trastuzumab and capecitabine, significantly improves overall survival and progression-free survival in patients with advanced HER2-positive breast cancer, including those with brain metastases.

Is Tukysa available in Asia?

Tukysa tablets are available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka. 

How can I get Tukysa tablets?

Indian Pharma Network (IPN) can facilitate the supply of Tukysa tablets (prescription medicine) to locations worldwide while adhering to legal requirements.

What makes Tukysa different from other HER2-targeted therapies? 

Tukysa specifically targets the HER2 protein and has shown efficacy in treating brain metastases, which is a common complication in advanced HER2-positive breast cancer. This makes it a valuable option for patients with central nervous system involvement.

How has Tukysa impacted the treatment landscape for HER2-positive cancers? 

Tukysa has expanded the options for treating HER2-positive breast and colorectal cancers, offering a targeted therapy that can be used after other treatments have failed. Its approval for use in brain metastases marks a significant advancement in cancer treatment.

Can pregnant women take Tukysa? 

No, Tukysa can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least one week after the last dose.

How is Tukysa administered? 

Tukysa is taken orally in tablet form, usually 300 mg twice a day, 12 hours apart. It can be taken with or without food, but should be swallowed whole, not crushed, broken, or chewed.

Has Tukysa received any new regulatory approvals?

Yes, Tukysa in combination with trastuzumab has been granted Priority Review by the FDA for the treatment of previously treated HER2-positive metastatic colorectal cancer. This designation is given to drugs that may offer significant improvements in treatment or provide a treatment where no adequate therapy exists.

Where is Tukysa available in India?

Tukysa  available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow,  Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc